Uptravi and Diverticulitis aggravated - a phase IV clinical study of FDA data
Summary:
Diverticulitis aggravated is found among people who take Uptravi, especially for people who are female, 60+ old, have been taking the drug for < 1 month.
The phase IV clinical study analyzes which people take Uptravi and have Diverticulitis aggravated. It is created by eHealthMe based on reports of 22,185 people who have side effects when taking Uptravi from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.
Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.
22,185 people reported to have side effects when taking Uptravi.
Among them, 77 people (0.35%) have Diverticulitis aggravated.
What is Uptravi?
Uptravi has active ingredients of selexipag. eHealthMe is studying from 22,190 Uptravi users for its effectiveness, alternative drugs and more.
What is Diverticulitis aggravated?
Diverticulitis aggravated (digestive disease which involves the formation of pouches (diverticula) within the bowel wall-aggravated) is found to be associated with 1,234 drugs and 352 conditions by eHealthMe.
Number of Uptravi and Diverticulitis aggravated reports submitted per year:

Time on Uptravi when people have Diverticulitis aggravated *:
- < 1 month: 69.23 %
- 1 - 6 months: 7.69 %
- 6 - 12 months: 7.69 %
- 1 - 2 years: 15.38 %
- 2 - 5 years: 0.0 %
- 5 - 10 years: 0.0 %
- 10+ years: 0.0 %
Gender of people who have Diverticulitis aggravated when taking Uptravi *:
- female: 54.55 %
- male: 45.45 %
Age of people who have Diverticulitis aggravated when taking Uptravi *:
- 0-1: 0.0 %
- 2-9: 0.0 %
- 10-19: 0.0 %
- 20-29: 0.0 %
- 30-39: 0.0 %
- 40-49: 1.54 %
- 50-59: 16.92 %
- 60+: 81.54 %
Common drugs people take besides Uptravi *:
- Opsumit: 41 people, 53.25%
- Adempas: 24 people, 31.17%
- Adcirca: 16 people, 20.78%
- Eliquis: 16 people, 20.78%
- Ambrisentan: 15 people, 19.48%
- Metformin: 9 people, 11.69%
- Xarelto: 8 people, 10.39%
- Aldactone: 6 people, 7.79%
- Letairis: 5 people, 6.49%
- Lasix: 3 people, 3.90%
Common side effects people have besides Diverticulitis aggravated *:
- Diarrhea: 43 people, 55.84%
- Headache (pain in head): 42 people, 54.55%
- Breathing Difficulty: 23 people, 29.87%
- Nausea (feeling of having an urge to vomit): 22 people, 28.57%
- Weight Decreased: 19 people, 24.68%
- Weakness: 19 people, 24.68%
- Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 18 people, 23.38%
- Dyspnea Exertional: 17 people, 22.08%
- Malaise (a feeling of general discomfort or uneasiness): 16 people, 20.78%
- Fatigue (feeling of tiredness): 16 people, 20.78%
Common conditions people have *:
- Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 71 people, 92.21%
- Constipation: 6 people, 7.79%
- Pulmonary Hypertension (increase in blood pressure in the lung artery): 5 people, 6.49%
- High Blood Cholesterol: 5 people, 6.49%
- Disease Progression: 3 people, 3.90%
- Systemic Sclerosis (Scleroderma) (an autoimmune or connective tissue disease. it is characterized by thickening of the skin): 1 person, 1.30%
- Cardiac Disorder: 1 person, 1.30%
- Blood Potassium Decreased: 1 person, 1.30%
- Biliary Cirrhosis Primary (primary biliary cirrhosis (pbc) is a long-term liver disease that damages the small bile ducts in the liver. the build-up of bile damages the liver): 1 person, 1.30%
* Approximation only. Some reports may have incomplete information.
Do you take Uptravi and have Diverticulitis aggravated?
Check whether Diverticulitis aggravated is associated with a drug or a conditionHow to use the study?
You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.
Related studies
How severe was Diverticulitis aggravated and when was it recovered:
Expand to all the drugs that have ingredients of selexipag:
Alternative drugs to, pros and cons of Uptravi:
- Uptravi (22,190 reports)
Common Uptravi side effects:
- Headache (pain in head): 7,340 reports
- Diarrhea: 5,641 reports
- Breathing difficulty: 5,339 reports
- Fatigue (feeling of tiredness): 2,871 reports
- Dizziness: 2,548 reports
- Muscle aches (muscle pain): 2,547 reports
- Pain: 2,507 reports
Browse all side effects of Uptravi:
a b c d e f g h i j k l m n o p q r s t u v w x y zDiverticulitis aggravated treatments and more:
- Diverticulitis aggravated (36 reports)
COVID vaccines that are related to Diverticulitis aggravated:
- Diverticulitis aggravated in Moderna COVID Vaccine
- Diverticulitis aggravated in Pfizer BioNTech Covid Vaccine
- Diverticulitis aggravated in Johnson and Johnson Covid Vaccine
Common drugs associated with Diverticulitis aggravated:
- Methotrexate: 3,412 reports
- Enbrel: 2,700 reports
- Humira: 2,595 reports
- Prednisone: 2,425 reports
- Aspirin: 2,005 reports
- Actemra: 1,798 reports
- Benicar: 1,773 reports
- Benicar hct: 1,349 reports
- Sulfasalazine: 1,327 reports
- Orencia: 1,318 reports
All the drugs that are associated with Diverticulitis aggravated:
- Diverticulitis aggravated (1,234 drugs)
Common conditions associated with Diverticulitis aggravated:
- Rheumatoid arthritis: 5,403 reports
- High blood pressure: 2,763 reports
- Multiple myeloma: 1,262 reports
- Pain: 1,176 reports
- Osteoporosis: 1,137 reports
- Multiple sclerosis: 1,122 reports
- Psoriasis: 1,070 reports
All the conditions that are associated with Diverticulitis aggravated:
- Diverticulitis aggravated (352 conditions)
How the study uses the data?
The study uses data from the FDA. It is based on selexipag (the active ingredients of Uptravi) and Uptravi (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
Who is eHealthMe?
With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Norco and Diabetes - a second ago
- Lamictal and Optic Neuropathy - 3 seconds ago
- Amoxil and Promacta drug interaction - 6 seconds ago
- Tracleer and Pulmonary Haemosiderosis - 17 seconds ago
- Nucynta and Alveolar Osteitis - 18 seconds ago
- Memantine and Atorvastatin Calcium drug interaction - 27 seconds ago
- Prolia and Psychosomatic Disease - 36 seconds ago
- Tegsedi and Lip Oedema - 36 seconds ago
- Simethicone and Metastases To Bone - 41 seconds ago
- Ryzolt and Metoprolol Tartrate drug interaction - 42 seconds ago